Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration

International Ophthalmology

Volumn 30, Issue 3, 2010, Pages 261-266

  Gamulescu, Maria Andreea ^a   Radeck, Viola ^a   Lustinger, Bruno ^a   Bianca Fink, Bruno ^a   Helbig, Horst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Age related macular degeneration; Anti VEGF treatment; Bevacizumab; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; EYE DISEASE; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SYSTEMIC DISEASE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; AGING; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; VISUAL ACUITY;

EID: 77955659425     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-009-9318-7     Document Type: Article

References (23)

1. Michaelson IC (1948) The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 68:137-180.
2. Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109:227-241.
3. Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
4. Kvanta A, Algvere PV, Berglin L, Seregard S (1996) Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37:1929-1934.
5. Hera R, Keramidas M, Peoc'h M (2005) Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 139(4):589-596.
6. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
7. Michels S, Rosenfeld PJ, Puliafito CA et al (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration; twelve-week results of an uncontrolled open-label study. Ophthalmology 112(6):1035-1047.
8. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36(4):331-335.
9. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60-65.
10. Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26(4):383-390. (Pubitemid 44197628)
11. Algvere PV, Steén B, Seregard S, Kvanta A (2008) A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol 86(5):482-489.
12. Bashshur ZF, Haddad ZA, Schakal A et al (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249-256.
13. Heier JS, Antoszyk AN, Pavan PR et al (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multi-dose trial. Ophthalmology 113(4):642.e1-4.
14. Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114(10):1868-1875.
15. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 114(6):850-857.
16. Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 145(2):239-248.
17. Raftery J, Clegg A, Jones J et al (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91:1244-1246.
18. Jaissle GB, Szurman P, Bartz-Schmidt KU, German Retina Society, German Society of Ophthalmology, German Professional Association of Ophthalmologists (2005) Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 222(5):390-395.
19. Emerson MV, Lauer AK, Flaxel CJ et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27(4):439-444.
20. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245(1):68-73.
21. Stewart MW (2007) Predicted biological activity of intravitreal bevacizumab. Retina 27(9):1196-1200.
22. Zhu Q, Ziemssen F, Henke-Fahle S et al (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115(10):1750-1755.
23. Keane PA, Liakopoulos S, Ongchin SC et al (2008) Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49(7):3115-3120.